Edition:
United States

Asahi Kasei Corp (3407.T)

3407.T on Tokyo Stock Exchange

1,496JPY
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
¥1,496
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,691,356
52-wk High
¥1,572
52-wk Low
¥1,042

Chart for

About

ASAHI KASEI CORPORATION is mainly engaged in chemical business. It has seven business segments. The Chemical segment offers petrochemicals, functional films, functional resins and others. The Textile segment offers synthetic textile and nonwoven fabrics. The Housing segment is engaged in the development and sale of housing, as... (more)

Overall

Beta: 0.77
Market Cap(Mil.): ¥2,112,340.00
Shares Outstanding(Mil.): 1,402.62
Dividend: 14.00
Yield (%): 1.86

Financials

  3407.T Industry Sector
P/E (TTM): 12.69 28.94 30.03
EPS (TTM): 118.65 -- --
ROI: 9.84 14.58 8.26
ROE: 13.60 19.88 19.46

BRIEF-Asahi Kasei's Group Operating Profit Seen Climbing 20% To Around 190 Bln Yen - Nikkei

* ASAHI KASEI CORP'S GROUP OPERATING PROFIT IS SEEN CLIMBING 20 PERCENT TO AROUND 190 BILLION YEN IN THE FISCAL YEAR ENDING MARCH 31 - NIKKEI

Jan 31 2018

Asahi Kasei unit wins $400 million U.S. defense contract: Pentagon

WASHINGTON Zoll Medical Corp, a unit of Asahi Kasei Corp, has been awarded a $400 million contract for deployable vital signs monitors, the Pentagon said on Friday.

Dec 08 2017

Asahi Kasei unit wins $400 million U.S. defense contract -Pentagon

WASHINGTON, Dec 8 Zoll Medical Corp, a unit of Asahi Kasei Corp, has been awarded a $400 million contract for deployable vital signs monitors, the Pentagon said on Friday. (Reporting by Mohammad Zargham; Editing by Eric Beech)

Dec 08 2017

Israel's Atox Bio raises $30 mln in Arix Bioscience-led round

JERUSALEM, Dec 4 Israeli biotech firm Atox Bio said on Monday it raised $30 million to further develop its leading product as a kidney treatment, in a fundraising round led by U.K.-based Arix Bioscience.

Dec 04 2017

Earnings vs. Estimates